◼ Archived
Health
🔮 fades ✓
Long ignored by drugmakers, preeclampsia is now a focus for WHO and biopharma
Preeclampsia, a long ignored pregnancy disorder, gains focus from WHO and biopharma.
Biopharma
7 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Biopharma
This hub groups 7 separate news trends connected to Biopharma, spanning July 7, 2026 through October 9, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 51 article observations and 48 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
Novartis and Bristol Myers have paused CAR-T trials after patient deaths, raising safety concerns in the biopharma industry.
◼ Archived
Business
🔮 fades ✓
Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
Eli Lilly's $2.88 billion acquisition of Merida Biosciences is poised to reshape the autoimmune disease treatment landscape.
◼ Archived
Business
🔮 fades ✓
Vacant lab space, shrinking workforce put Mass. in ‘unique position’ for biotech bounceback
Massachusetts' biotech sector faces a paradox: job losses amid a rebound in investment.
◼ Archived
Business
🔮 fades ✓
FDA approves Replimune melanoma drug previously rejected twice
Replimune's melanoma drug wins FDA approval on third attempt, but stock price falls.
◼ Archived
Business
🔮 fades ✓
Unpacking Anthropic's 100-day sprint into biopharma: Nobel hires, M&A and major ambition
Anthropic is aggressively expanding into the biopharma sector through a 100-day sprint involving Nobel hires, M&A activity, and new research tools.
◼ Archived
Business
🔮 fades ✓
Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles
Vertex Pharmaceuticals is entering the endocrine disease market with a $10 billion acquisition of Crinetics.